HUE042330T2 - Módszer alumínium adjuvánsok és alumíniummal adjuvált vakcinák megóvására - Google Patents

Módszer alumínium adjuvánsok és alumíniummal adjuvált vakcinák megóvására

Info

Publication number
HUE042330T2
HUE042330T2 HUE11712653A HUE11712653A HUE042330T2 HU E042330 T2 HUE042330 T2 HU E042330T2 HU E11712653 A HUE11712653 A HU E11712653A HU E11712653 A HUE11712653 A HU E11712653A HU E042330 T2 HUE042330 T2 HU E042330T2
Authority
HU
Hungary
Prior art keywords
alum
preserving
adjuvants
adjuvanted vaccines
adjuvanted
Prior art date
Application number
HUE11712653A
Other languages
English (en)
Inventor
Jeffrey Drew
David Woodward
Amanda Corteyn
Original Assignee
Stabilitech Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1005522.6A external-priority patent/GB201005522D0/en
Priority claimed from GBGB1005518.4A external-priority patent/GB201005518D0/en
Application filed by Stabilitech Biopharma Ltd filed Critical Stabilitech Biopharma Ltd
Publication of HUE042330T2 publication Critical patent/HUE042330T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
HUE11712653A 2010-03-31 2011-03-31 Módszer alumínium adjuvánsok és alumíniummal adjuvált vakcinák megóvására HUE042330T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1005522.6A GB201005522D0 (en) 2010-03-31 2010-03-31 Method for preserving alum-adjuvanted vaccines
GBGB1005518.4A GB201005518D0 (en) 2010-03-31 2010-03-31 Preservation of alum-adjuvanted vaccines

Publications (1)

Publication Number Publication Date
HUE042330T2 true HUE042330T2 (hu) 2019-06-28

Family

ID=43971221

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11712653A HUE042330T2 (hu) 2010-03-31 2011-03-31 Módszer alumínium adjuvánsok és alumíniummal adjuvált vakcinák megóvására

Country Status (13)

Country Link
US (1) US9101607B2 (hu)
EP (1) EP2552410B1 (hu)
JP (1) JP6023696B2 (hu)
KR (1) KR101819250B1 (hu)
CN (1) CN102892409B (hu)
AU (1) AU2011234268B2 (hu)
BR (1) BR112012025044A2 (hu)
CA (1) CA2795050C (hu)
DK (1) DK2552410T3 (hu)
ES (1) ES2708989T3 (hu)
GB (1) GB2499480A (hu)
HU (1) HUE042330T2 (hu)
WO (1) WO2011121305A2 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011121306A1 (en) * 2010-03-31 2011-10-06 Stabilitech Ltd. Stabilisation of viral particles
GB2490644A (en) 2010-03-31 2012-11-07 Stabilitech Ltd Excipients for stabilising viral particles, polypeptides or biological material
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
US9588123B2 (en) * 2014-04-11 2017-03-07 Surmodics Ivd, Inc. Compositions and methods for in vitro diagnostic tests including zwitterionic solubilization reagent
GB201406569D0 (en) * 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
AR111760A1 (es) * 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
CN113750228B (zh) * 2021-09-25 2024-02-20 大连理工大学 一种冷冻保护剂在铝佐剂中的应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927208A (en) 1973-05-14 1975-12-16 Rit Rech Ind Therapeut Live bovine adenovirus vaccines, preparation thereof and method of vaccination using them
US4631189A (en) 1980-03-10 1986-12-23 Da Vinci Laboratories, a division of FoodScience Corporation N,N-dimethylglycine and use in immune response
JPS6013718A (ja) 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst Ｂ型肝炎ワクチン
JPS60193925A (ja) 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
JPS61189228A (ja) 1985-02-19 1986-08-22 Nippon Sekijiyuujishiya 血液凝固第８因子製剤の製法
US4950596A (en) 1985-03-04 1990-08-21 The Dow Chemical Company Stabilization of intracellular enzymes
JPS6238173A (ja) 1985-08-13 1987-02-19 三菱レイヨン株式会社 抗血液凝固剤
US5169758A (en) 1986-05-02 1992-12-08 Boehringer Mannheim Gmbh Stabilized, NAD(P)H-dependent, soluble nitrate reductase, a process for the preparation thereof and a reagent containing it
NZ221306A (en) 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
DE3782737T3 (de) * 1987-08-21 1999-05-20 Imcera Group Inc., Northbrook, Ill. Stabilisierung von Wachstumshormonen.
GB8826429D0 (en) 1988-11-11 1988-12-14 Univ Leeds Ind Service Ltd Enzyme stabilisation systems
DE69032102T2 (de) 1989-08-15 1998-06-25 Massachusetts Inst Technology Stabilisierte impfstoffzusammensetzungen
AU650045B2 (en) 1990-09-12 1994-06-09 Lifecell Corporation Method and apparatus for cryopreparation dry stabilization and rehydration of biological suspensions
ZA936095B (en) 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
AU5543294A (en) * 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
CN100360184C (zh) 1995-07-27 2008-01-09 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂
GB9521806D0 (en) 1995-10-25 1996-01-03 Cortecs Ltd Preservation methods
FR2746109B1 (fr) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
CA2242035C (en) 1997-07-01 2004-11-23 Transgene S.A. Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
AU5459698A (en) 1997-11-26 1999-06-15 Universal Preservation Technologies, Inc. Preservation of sensitive biological samples by vitrification
EP1977764A1 (en) 1998-11-16 2008-10-08 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
AUPQ347199A0 (en) 1999-10-15 1999-11-11 Csl Limited Novel polypeptide fragments
AU2001275371B9 (en) * 2000-06-08 2007-06-07 Powderject Vaccines, Inc. Powder compositions
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US20040110267A1 (en) 2000-12-15 2004-06-10 Stratagene Room temperature stable competent cells
EP1399131A2 (en) 2001-06-08 2004-03-24 Powderject Vaccines, Inc. Spray freeze-dried compositions
US7101693B2 (en) 2001-09-07 2006-09-05 Brigham Young University Plasticized hydrophilic glasses for improved stabilization of biological agents
JP4936618B2 (ja) * 2001-09-21 2012-05-23 株式会社ノエビア 微細エマルション組成物
US20040161776A1 (en) * 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
EP1946776B1 (en) 2002-02-27 2017-01-18 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
WO2004002534A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Use of dimethyl sulfone as isotonicity agent
JP2006514538A (ja) 2002-07-10 2006-05-11 トランスジーン ソシエテ アノニム 細胞受容体への結合が除去された改変アデノウイルス繊維
AU2003272174A1 (en) 2002-10-21 2004-05-04 Biotage Ab Use of osmolytes to heat stabilise luciferase and/or apyrase
AU2003297833A1 (en) 2002-12-10 2004-06-30 Schering-Plough Ltd. Canine rankl and methods for preparing and using the same
US20060247167A1 (en) 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
US7642077B2 (en) 2003-12-08 2010-01-05 Genencor International, Inc. Biocomposite comprising co-precipitate of enzyme, silicate and polyamine
WO2005062709A2 (en) 2003-12-30 2005-07-14 Virumar Pituach Tarkivim Ltd. Integrated viral complexes, methods of production thereof, vaccines containing same and methods of use thereof
CA2558676C (en) 2004-03-03 2019-04-16 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US20060058238A1 (en) 2004-09-15 2006-03-16 Lee Laurent-Applegate Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
MX366832B (es) 2004-10-01 2019-07-24 Ramscor Inc Composiciones de farmaco de liberacion sostenida convenientemente implantables.
MX2007009091A (es) 2005-01-28 2008-01-11 Wyeth Corp Formulaciones de polipeptido liquidas estabilizadas.
GB0502661D0 (en) 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
TWI398272B (zh) 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
CN101155914B (zh) 2005-04-08 2013-03-06 阿戈斯治疗公司 树状细胞组合物和方法
US20090155351A1 (en) 2005-10-04 2009-06-18 Alk-Abello A/S Solid Vaccine Formulation
JP5138601B2 (ja) 2005-11-21 2013-02-06 サノフィ パストゥール リミテッド 組換えウイルス安定化製剤
KR101385805B1 (ko) 2005-11-30 2014-04-16 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 신규 펩티드 화합물
WO2008051245A2 (en) 2005-12-02 2008-05-02 Novartis Ag Nanoparticles for use in immunogenic compositions
CA2642270A1 (en) * 2006-02-15 2007-08-23 Imclone Systems Incorporated Antibody formulation
ES2286951B1 (es) * 2006-05-26 2008-10-01 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas bioadhesivas para la administracion de moleculas biologicamente activas.
NZ576563A (en) 2006-11-03 2012-09-28 Alphavax Inc Alphavirus and alphavirus replicon particle formulations and methods
GB0705245D0 (en) 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
US8444991B2 (en) * 2007-03-22 2013-05-21 The Regents Of The University Of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
EP2150537A4 (en) * 2007-06-01 2010-09-22 Acologix Inc STABLE PEPTIDE FORMULATION AT HIGH TEMPERATURE
WO2009015343A2 (en) * 2007-07-25 2009-01-29 Bioe, Inc. Differentiation of multi-lineage progenitor cells to chondrocytes
US20090123436A1 (en) 2007-11-08 2009-05-14 Surmodics, Inc. Cryopreservative compositions and methods
BRPI0918988A2 (pt) 2008-09-24 2015-12-01 Stabilitech Ltd métodos para preservar um polipeptídeo e um imunógeno de vacina, e para preparar uma vacina, pó seco, produto preservado, frasco selado, ampola ou seringa, uso de um excipiente, e, vacina.
US20110212127A1 (en) 2008-09-24 2011-09-01 Stabilitech Ltd. Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine
CN101670104A (zh) 2009-09-24 2010-03-17 浙江大学 一种含人参皂甙的油佐剂及其制备方法
WO2011121306A1 (en) 2010-03-31 2011-10-06 Stabilitech Ltd. Stabilisation of viral particles

Also Published As

Publication number Publication date
BR112012025044A2 (pt) 2016-06-21
GB2499480A (en) 2013-08-21
ES2708989T3 (es) 2019-04-12
WO2011121305A2 (en) 2011-10-06
US20130156797A1 (en) 2013-06-20
WO2011121305A3 (en) 2011-11-24
US9101607B2 (en) 2015-08-11
JP2013523705A (ja) 2013-06-17
CN102892409B (zh) 2015-12-09
CN102892409A (zh) 2013-01-23
AU2011234268B2 (en) 2015-07-02
DK2552410T3 (en) 2019-02-18
AU2011234268A1 (en) 2012-09-27
CA2795050C (en) 2018-05-22
EP2552410B1 (en) 2018-10-24
KR101819250B1 (ko) 2018-01-16
GB201216472D0 (en) 2012-10-31
EP2552410A2 (en) 2013-02-06
KR20130012956A (ko) 2013-02-05
CA2795050A1 (en) 2011-10-06
JP6023696B2 (ja) 2016-11-09

Similar Documents

Publication Publication Date Title
HK1245128A1 (zh) 針對人腸道病毒的抗原及疫苗
IL233235A0 (en) Devices and methods for increasing bone growth
EP2588011A4 (en) MEDICAL DEVICES AND METHODS FOR CUTTING AND / OR EVACUATING TISSUE
EP2773274A4 (en) DEVICES AND METHODS FOR TISSUE EXTRACTION
EP2723255A4 (en) DEVICES AND METHODS FOR TISSUE EXTRACTION
GB201006079D0 (en) Surgical device and methods
EP2540337A4 (en) MICRO NEEDLE DEVICE AND METHOD FOR PREPARING THE SAME
GB201216472D0 (en) Method for preserving alum adjuvants and alum-adjuvanted vaccines
EP2550298A4 (en) COMPOSITIONS AND METHODS FOR PREPARING SELF-ADJUVANT VACCINES AGAINST MICROBES AND TUMORS
EP2773410A4 (en) FAN AND MEDICAL DEVICE AND METHOD
EP2657188A4 (en) FLUOROGRAPHIC AND METHOD FOR PREPARING THE SAME
IL269825A (en) Method and device for tissue approximation
EP2614072A4 (en) VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
EP2825196A4 (en) ADJUVANT AND VACCINE COMPOSITIONS
SI2525953T1 (sl) Postopek in naprava za pripravo in razstrupljanje
SG10201503450WA (en) Vaccine against beta-herpesvirus infection and use thereof
EP2680787A4 (en) SURGICAL IMPLANT AND METHOD THEREOF
GB2495522B (en) Surgical device and methods
EP2925402A4 (en) IMPLANTING DEVICE FOR TISSUE BONDING AND METHOD
EP2720621A4 (en) METHOD AND DEVICE FOR RECONCILIATION OF FABRICS
IL229303A0 (en) Devices and methods to fasten tissue
GB201000399D0 (en) Medical device and method
GB201021953D0 (en) Medical device and method
EP2929894A4 (en) VACCINE ADJUVANS, PREPARATION AND VACCINES THEREOF
GB201013006D0 (en) Vaccine